By Charles Piller – Science
image caption: There are two hallmarks of Alzheimer’s dementia, amyloid-beta protein deposits known as plaques among brain cells (yellow-orange bundles), and tangles of a protein called tau inside neurons (wiry objects inside the neuron), but several potential antibody therapies target just amyloid.Kateryna Kon/Science Source
Woman’s brain hemorrhage while receiving Eisai’s widely heralded lecanemab heightens concerns overs its safety
A 65-year-old woman who was receiving a promising experimental treatment to slow the cognitive decline caused by her early Alzheimer’s disease recently died from a massive brain hemorrhage that some researchers link to the drug. The clinical trial death, described in an unpublished case report Science has obtained, is the second thought to be associated with the antibody called lecanemab. The newly disclosed fatality intensifies questions about its safety and how widely lecanemab should be prescribed if ultimately approved by regulators.
The woman, who received infusions of the antibody as part of the trial, suffered a stroke and a type of swelling and bleeding previously seen with such antibodies, which bind to and remove forms of amyloid-beta, a protein widely theorized to cause Alzheimer’s. After the stroke was diagnosed in an emergency room at Northwestern University Medical Center in Chicago, she was given a common intervention, the powerful blood-clot busting medication tissue plasminogen activator (tPA). Substantial bleeding immediately followed throughout her brain’s outer layer immediately followed, and the woman died a few days later, according to the case report.
